Search Results - "Wamil, Barbara"

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    CM101-Mediated Recovery of Walking Ability in Adult Mice Paralyzed by Spinal Cord Injury by Wamil, Artur W., Wamil, Barbara D., Hellerqvist, Carl G.

    “…CM101, an antiangiogenic polysaccharide derived from group B streptococcus, was administered by i.v. injection 1 hr post-spinal-cord crush injury in an effort…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Macrophage stimulation using a group B-streptococcus exotoxin (CM101) leads to axonal regrowth in the injured optic nerve by Ohlsson, Marcus, Mattsson, Per, Wamil, Barbara D, Hellerqvist, Carl G, Svensson, Mikael

    “…A group B-streptococcus exotoxin (CM101) was administered following optic nerve injury in adult rats in order to analyze putative effects on macrophages, glial…”
    Get more information
    Journal Article
  4. 4

    Identification of a Novel Membrane Protein, HP59, with Therapeutic Potential as a Target of Tumor Angiogenesis by Fu, C, Bardhan, S, Cetateanu, N D, Wamil, B D, Wang, Y, Yan, H P, Shi, E, Carter, C, Venkov, C, Yakes, F M, Page, D L, Lloyd, R S, Mernaugh, R L, Hellerqvist, C G

    Published in Clinical cancer research (01-12-2001)
    “…CM101, a polysaccharide isolated from the culture medium of Group B streptococcus, a neonatal pathogen, targets pathological angiogenesis and inhibits tumor…”
    Get full text
    Journal Article
  5. 5

    An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10) by Moreno, Victor, Kim, Tae Min, Rha, Sun Young, Longo, Federico, Sathornsumetee, Sith, Zhang, Shirong, Hirschberg, Yulia, Pramanik, Barnali, Wamil, Barbara D, Kiss, Igor

    Published in Journal of clinical oncology (20-05-2020)
    “…Abstract only 3520 Background: Prior studies have confirmed the efficacy and safety of ceritinib in patients (pts) with advanced ALK+ non-small cell lung…”
    Get full text
    Journal Article
  6. 6

    CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis by YAKES, F. Michael, WAMIL, Barbara D, FENGLEI SUN, YAN, He-Ping, CARTER, Clint E, HELLERQVIST, Carl G

    Published in Cancer research (Chicago, Ill.) (15-10-2000)
    “…CM101, a bacterial polysaccharide exotoxin produced by group B Streptococcus (GBS), also referred to as GBS toxin, has been shown to target pathological…”
    Get full text
    Journal Article
  7. 7

    CM101 stimulates cutaneous wound healing through an anti-angiogenic mechanism by NANNEY, Lillian B, WAMIL, Barbara D, WHITSITT, Jeffrey, CARDWELL, Nancy L, DAVIDSON, Jeffrey M, YAN, He-Ping, HELLERQVIST, Carl G

    Published in Angiogenesis (London) (2001)
    “…CM101, an anti-pathoangiogenic polysaccharide derived from group B streptococcus, has been shown to inhibit inflammatory angiogenesis and accelerate wound…”
    Get full text
    Journal Article
  8. 8

    Isolation and identification of the group B streptococcal toxin CM101 from infants with sepsis by Sundell, Håkan W., Yan, Heping, Carter, Clint E., Wamil, Barbara D., Wu, Kanning, Gaddipati, Rao, Li, Dongbei, Hellerqvist, Carl G.

    Published in The Journal of pediatrics (01-09-2000)
    “…Objective: To determine whether the group B streptococcal (GBS) polysaccharide exotoxin CM101, which induces a complement-activated cytokine-driven…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Functional studies on the anti-pathoangiogenic properties of CM101 by Yan, H P, Carter, C E, Wang, E Z, Page, D L, Washington, K, Wamil, B D, Yakes, F M, Thurman, G B, Hellerqvist, C G

    Published in Angiogenesis (London) (1998)
    “…Group B streptococcus (GBS) isolated from human neonates diagnosed with sepsis and respiratory distress produces a polysaccharide exotoxin (CM101) which has…”
    Get full text
    Journal Article
  11. 11

    Phase I study of the antineovascularization drug CM101 by DEVORE, R. F, HELLERQVIST, C. G, YORK, G. E, ZHANG, M.-H, JOHNSON, D. H, WAKEFIELD, G. B, WAMIL, B. D, THURMAN, G. B, MINTON, P. A, SUNDELL, H. W, YAN, H.-P, CARTER, C. E, WANG, Y.-F

    Published in Clinical cancer research (01-03-1997)
    “…CM101 is a bacterial polysaccharide that induces neovascular inflammation in malignant tumors. Fifteen patients with refractory malignancies received CM101…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14